These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29203894)

  • 1. Combining intratumoral Treg depletion with androgen deprivation therapy (ADT): preclinical activity in the Myc-CaP model.
    Shen YC; Ghasemzadeh A; Kochel CM; Nirschl TR; Francica BJ; Lopez-Bujanda ZA; Carrera Haro MA; Tam A; Anders RA; Selby MJ; Korman AJ; Drake CG
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):113-125. PubMed ID: 29203894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.
    Benzon B; Glavaris SA; Simons BW; Hughes RM; Ghabili K; Mullane P; Miller R; Nugent K; Shinder B; Tosoian J; Fuchs EJ; Tran PT; Hurley PJ; Vuica-Ross M; Schaeffer EM; Drake CG; Ross AE
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):126-136. PubMed ID: 29556048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer.
    Obradovic AZ; Dallos MC; Zahurak ML; Partin AW; Schaeffer EM; Ross AE; Allaf ME; Nirschl TR; Liu D; Chapman CG; O'Neal T; Cao H; Durham JN; Guner G; Baena-Del Valle JA; Ertunc O; De Marzo AM; Antonarakis ES; Drake CG
    Clin Cancer Res; 2020 Jul; 26(13):3182-3192. PubMed ID: 32173650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
    Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
    Hawley JE; Obradovic AZ; Dallos MC; Lim EA; Runcie K; Ager CR; McKiernan J; Anderson CB; Decastro GJ; Weintraub J; Virk R; Lowy I; Hu J; Chaimowitz MG; Guo XV; Zhang Y; Haffner MC; Worley J; Stein MN; Califano A; Drake CG
    Cancer Cell; 2023 Nov; 41(11):1972-1988.e5. PubMed ID: 37922910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
    Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of CD4
    Wang C; Chen J; Zhang Q; Li W; Zhang S; Xu Y; Wang F; Zhang B; Zhang Y; Gao WQ
    Cell Res; 2018 Nov; 28(11):1103-1117. PubMed ID: 30297869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
    Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
    J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
    Hahn S; Nesslinger NJ; Drapala RJ; Bowden M; Rennie PS; Pai HH; Ludgate C; Nelson BH
    Int J Cancer; 2009 Dec; 125(12):2871-8. PubMed ID: 19554630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
    Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Numb
    Guo Y; Zhang K; Cheng C; Ji Z; Wang X; Wang M; Chu M; Tang DG; Zhu HH; Gao WQ
    Clin Cancer Res; 2017 Nov; 23(21):6744-6756. PubMed ID: 28751447
    [No Abstract]   [Full Text] [Related]  

  • 14. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer.
    Terrisse S; Goubet AG; Ueda K; Thomas AM; Quiniou V; Thelemaque C; Dunsmore G; Clave E; Gamat-Huber M; Yonekura S; Ferrere G; Rauber C; Pham HP; Fahrner JE; Pizzato E; Ly P; Fidelle M; Mazzenga M; Costa Silva CA; Armanini F; Pinto F; Asnicar F; Daillère R; Derosa L; Richard C; Blanchard P; Routy B; Culine S; Opolon P; Silvin A; Ginhoux F; Toubert A; Segata N; McNeel DG; Fizazi K; Kroemer G; Zitvogel L
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35296557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ vaccination combined with androgen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice.
    Akins EJ; Moore ML; Tang S; Willingham MC; Tooze JA; Dubey P
    Cancer Res; 2010 May; 70(9):3473-82. PubMed ID: 20406970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
    Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
    Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Sinha AA; Pomroy FE; Wilson MJ
    Anticancer Res; 2016 Aug; 36(8):3847-54. PubMed ID: 27466486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.